Efavirenz
Efavirenz
- Efavirenz is supplied in pharmacies and by registered pharmaceutical suppliers worldwide (brands include Sustiva, Stocrin and the fixed‑dose combination Atripla). Legally it is prescription‑only in Canada and most countries; however, some pharmacies or online sellers may offer it without a prescription (this is not recommended or necessarily legal).
- Efavirenz is an antiretroviral drug used to treat and help prevent HIV‑1 infection; it is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase and reduces viral replication.
- The usual adult dose is 600 mg orally once daily (with or after food); for PEP it is typically given as 600 mg daily as part of a combination regimen for 28 days; paediatric dosing is weight‑based.
- Efavirenz is administered orally as tablets (commonly 600 mg and 200 mg) and capsules (including 50 mg paediatric capsules); it is also available in fixed‑dose combination tablets (e.g., Atripla).
- Effects can begin within hours: CNS effects (dizziness, vivid dreams, insomnia) often appear within the first hours after dosing and plasma concentrations typically peak in about 3–5 hours.
- Clinically efavirenz is dosed once daily (effects lasting ~24 hours); the drug has a long elimination half‑life (roughly 40–55 hours), so plasma levels persist for several days after dosing.
- Avoid heavy alcohol use while taking efavirenz: alcohol can worsen central nervous system side effects (drowsiness, dizziness, impaired concentration) and may increase liver strain.
- The most common side effects are central nervous system symptoms — for example, dizziness, vivid dreams and insomnia (other common effects include nausea and rash).
- Would you like to try efavirenz without a prescription?
Basic Efavirenz Information
- INN (International Nonproprietary Name): Efavirenz — an antiretroviral non-nucleoside reverse transcriptase inhibitor (NNRTI) used for management and prevention of HIV‑1 infection; Latin: efavirenzum.
- Brand Names Available In Canada (English): Sustiva and Atripla marketed in Canada (600 mg tablet; 200 mg capsule where applicable) with distribution by BMS Canada and Gilead Sciences.
- ATC Code: J05AG03 for efavirenz monotherapy; combination formulation listed under J05AR06 (emtricitabine/tenofovir/efavirenz).
- Forms & Dosages: Tablet 600 mg and 200 mg; capsule 50 mg (pediatric) and 200 mg; fixed‑dose combination Atripla (600 mg efavirenz + 200 mg emtricitabine + 300 mg tenofovir) in blister packaging.
- Manufacturers In Canada (English): Originator Bristol‑Myers Squibb (Sustiva), combination marketed by Gilead (Atripla); generics available globally from Teva, Mylan, Zentiva, Sandoz and others.
- Registration Status In Canada (English): Registered and marketed in Canada; globally approved since late 1990s and WHO‑listed as an essential medicine.
- OTC / Rx Classification: Prescription only (Rx); not available OTC.
Latest Research Highlights
Patients and clinicians ask whether efavirenz remains relevant after newer drugs arrived.
Canadian surveillance and international cohort updates from 2022–2025 show efavirenz retains strong virological effectiveness within combination ART but has been deprioritised in many programmes in favour of integrase inhibitors such as dolutegravir.
Reports from Canadian HIV treatment centres note ongoing use in patients who are stable on efavirenz‑containing regimens and in settings where fixed‑dose Atripla remains accessible.
Systematic reviews in the period continue to report persistent central nervous system adverse events and concerns about teratogenicity in people of child‑bearing potential, prompting guideline updates internationally.
WHO data list efavirenz’s Defined Daily Dose as 0.6 g/day and note it is included on the WHO Model List of Essential Medicines.
| International Trials (2022–2025) | Canadian Observational Data (2022–2025) |
|---|---|
| Maintained virological suppression in combination ART; higher CNS adverse event reports versus integrase inhibitors. | Continued viral control among adherent stable patients; selective switching based on tolerability and pregnancy planning. |
| Guideline shifts favour dolutegravir for initial therapy due to tolerability and neuropsychiatric safety profiles. | Use retained where Atripla or Sustiva is locally available and where regimen stability is prioritised. |
Data Highlight: WHO DDD 0.6 g/day; WHO‑listed essential medicine; guideline emphasis moved toward integrase inhibitors for many new starts.
Clinical Effectiveness In Canada
People commonly want to know whether efavirenz still suppresses HIV effectively in Canadian practice.
Health Canada approval plus decades of clinical experience confirm efavirenz achieves durable viral suppression when used as part of a three‑drug ART backbone.
Older randomised controlled trials underpin efficacy claims and Canadian cohort data support continued viral control in adherent patients.
Efavirenz carries ATC classification J05AG03 and is available in Canada as Sustiva and in the fixed‑dose combination Atripla.
- Virological Suppression: Undetectable viral load when used within guideline‑recommended combination ART and with adherence.
- Adherence Threshold: Once‑daily dosing supports adherence for patients who prefer a single daily pill.
- Resistance: Monotherapy is contraindicated; resistance risk decreases with full combination therapy.
| Province / Territory | Likely Reimbursement Pathway |
|---|---|
| Ontario (ODB) | Public formulary listing or special authorisation; private insurance common. |
| Quebec (RAMQ) | Provincial coverage subject to criteria; bilingual counselling expected. |
| British Columbia (PharmaCare) | PharmaCare reimbursement possible with prescriber documentation. |
| Other Provinces/Territories | Coverage varies; special access or private plans often used. |
Pharmacy access typically includes major chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs where bilingual labels and counselling are expected.
Indications And Expanded Uses
Patients often ask whether efavirenz can be used for prevention as well as treatment.
Approved indications in Canada and internationally are treatment of HIV‑1 infection as part of combination ART and use in PEP regimens in combination with other agents.
- Approved Indications: Treatment of HIV‑1 infection (in combination); post‑exposure prophylaxis as part of a combined 28‑day regimen.
- Common Off‑Label Scenarios: Limited use in some resource‑limited prophylactic strategies or locally adapted regimens where FDCs simplify dispensing.
| Regimen Type | Typical Efavirenz Use |
|---|---|
| Chronic HIV Treatment | 600 mg once daily within a three‑drug ART regimen, lifelong therapy. |
| Post‑Exposure Prophylaxis (PEP) | 600 mg daily in combination for 28 days as part of PEP regimens. |
Clinicians should clearly explain approved versus off‑label use, and women of child‑bearing potential need detailed contraceptive counselling because of teratogenicity concerns.
Composition And Brand Landscape
People frequently ask what’s in the pill and whether generics are the same as brand.
Efavirenz (INN efavirenz) is available in Canada as 600 mg tablets and as part of fixed‑dose Atripla (efavirenz/emtricitabine/tenofovir).
| Brand | Form | Typical Packaging In Canada |
|---|---|---|
| Sustiva | 600 mg tablet | Blister packs; BMS Canada distribution |
| Atripla | Fixed‑dose tablet (EFV 600 mg + FTC 200 mg + TDF 300 mg) | Blister packs; Gilead distribution |
| Generic Efavirenz | 600 mg tablet; 200 mg tablet; 50 mg caps | Bottles or blisters from global generics (Teva, Mylan, Sandoz) |
- FAQ: Generics contain the same active efavirenz but packaging, excipients and DINs differ; pharmacists can show DIN and manufacturer on request.
- FAQ: Indigenous health programmes may prefer generics supplied via federal procurement for continuity.
Urban clinics often stock fixed‑dose combinations to simplify adherence while rural dispensaries may receive different pack formats.
Contraindications And Special Precautions
Patients often worry about who should avoid efavirenz and why.
Absolute contraindications include known hypersensitivity to efavirenz and severe hepatic impairment.
- Absolute Contraindications: Hypersensitivity to efavirenz; severe liver impairment; co‑administration with explicitly contraindicated drugs such as voriconazole and elbasvir/grazoprevir, and St. John’s Wort.
- Precautions: History of psychiatric illness, seizures or epilepsy; monitor for new or worsening psychiatric symptoms.
Safety Note: Screen for mental health history during prescribing and document contraceptive counselling for women of reproductive potential.
Pharmacists commonly detect over‑the‑counter herbals such as St. John’s Wort during screening and should counsel patients to stop those products when efavirenz is started.
Dosage Guidelines (Canadian Context)
A common practical question is how to take efavirenz and what to do with missed or extra doses.
The standard adult dose is 600 mg once daily, preferably with or after food.
| Population | Recommended Dose | Notes / Adjustments |
|---|---|---|
| Adults | 600 mg once daily | Take with/after food; lifelong in combination ART. |
| Pediatrics | Weight‑band dosing (50 mg capsules available) | Use appropriate weight bands; ≥35 kg often receive 600 mg. |
| PEP | 600 mg daily (in combination) | Typically a 28‑day course. |
| Hepatic Impairment | Avoid in moderate–severe impairment | Monitor liver function if used in mild dysfunction. |
- Missed Dose: Take as soon as remembered unless close to the next dose; do not double dose.
- Overdose: Can cause severe CNS effects; provide supportive care and consider activated charcoal if recent ingestion.
Remote clinics often dispense multi‑month supplies, so pharmacists should counsel on storage below 30°C and protection from moisture.
Interactions Overview
Many patients ask which drugs or habits clash with efavirenz.
Efavirenz is a cytochrome P450 (CYP3A) inducer and interacts with numerous medications, reducing concentrations or increasing risks of adverse effects.
| Drug / Substance | Effect | Recommended Action |
|---|---|---|
| Voriconazole | Contraindicated — interaction risk | Avoid co‑administration |
| Elbasvir / Grazoprevir | Contraindicated | Do not co‑administer |
| St. John’s Wort | Significant CYP induction — reduced efavirenz levels and unpredictable effects | Advise stopping herbal supplement |
| Certain Benzodiazepines | Increased or decreased exposure; risk of adverse CNS effects | Review alternatives and monitor closely |
| Hormonal Contraceptives | Possible reduced efficacy in some cases | Provide contraceptive counselling and consider additional methods |
Food increases efavirenz bioavailability, so counsel patients on consistent timing with meals when prescribed.
Pharmacists should run interaction checks, ask about OTC herbals, alcohol and cannabis use, and review benzodiazepine prescriptions.
Cultural Perceptions And Patient Habits In Canada
Many patients wonder how cultural or regional factors affect efavirenz use.
Canadian community feedback and online forums (2022–2025) show once‑daily dosing is appreciated but neuropsychiatric side effects push many to prefer newer agents.
- Common Patient Concerns: Vivid dreams, dizziness, mood changes, pregnancy risks, and cost or formulary coverage.
- Counselling Tips By Population: Provide bilingual counselling in English/French; engage Indigenous health programmes with sensitivity to distrust of pharmaceuticals; prioritise regimen continuity for long‑term stable patients.
| Setting | Access Barrier |
|---|---|
| Urban | Clinic choice and formulary navigation; easier access to specialist care |
| Rural / Remote | Distance to clinic, supply interruptions, stigma concerns; med sync and telepharmacy helpful |
Pharmacists in urban centres often act as first‑line counsellors and can help patients weigh switching versus staying on efavirenz based on individual priorities.
Availability And Pricing Patterns (Canada Versus US)
Cost and availability are frequent practical questions for patients considering efavirenz or Atripla.
Efavirenz and Atripla are available in Canada with distribution by BMS and Gilead and with generic producers supplying alternatives.
| Pricing Source | How To Check |
|---|---|
| Provincial Drug Plans (ODB, PharmaCare, RAMQ) | Contact plan or pharmacist with DIN and prescription details for coverage confirmation |
| Private Insurance / Employer Plans | Submit claim with DIN; check formulary tiers |
| Online / Cross‑Border Purchases | Packaging and DINs may differ; verify provincial reimbursement eligibility before ordering |
- How To Check Coverage: Ask your pharmacist for the drug DIN and contact your provincial plan or insurer.
- Cross‑Border Caveats: US packaging and formulations may differ and could affect reimbursement or counselling.
In our online pharmacy, efavirenz is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.
Comparable Medicines And Prescribing Preferences
Patients often ask what the alternatives are and why a prescriber might switch therapy.
Alternatives include other NNRTIs like rilpivirine and etravirine, and integrase inhibitors such as dolutegravir which are increasingly preferred for initial therapy because of improved tolerability.
- Pros Of Efavirenz: Once‑daily dosing and long clinical experience with durable viral suppression when used in combination ART.
- Cons Of Efavirenz: Higher rates of CNS adverse events and teratogenicity concerns compared with some alternatives.
| Drug | Efficacy | Side‑Effect Profile | Cost Consideration |
|---|---|---|---|
| Efavirenz | High when used in combination | CNS effects common; hepatic monitoring required | Generic options lower cost; provincial coverage varies |
| Dolutegravir | High; favoured for initial therapy | Generally better tolerability | Often preferred on formularies for new starts |
| Rilpivirine | Good for patients with low baseline viral loads | Fewer CNS effects but requires food for absorption | Formulary placement varies by province |
Pharmacists should help patients compare pros and cons in the context of comorbidities, pregnancy planning and provincial formulary coverage.
Frequently Asked Questions
Is efavirenz still a good option?
Yes, efavirenz remains a valid option for many patients who are stable on their regimen, but clinicians and patients should discuss switching when side effects or pregnancy planning are concerns.
What about pregnancy?
Women of child‑bearing potential should discuss contraception and alternative regimens because of teratogenicity concerns; specialist‑led counselling via maternal health services is often recommended.
Can I take herbal supplements?
Avoid St. John’s Wort while taking efavirenz and always consult your pharmacist before starting any herbal product.
Will my provincial plan cover it?
Coverage depends on province and on the DIN; contact ODB, PharmaCare, RAMQ or your private insurer and ask your pharmacist to confirm reimbursement pathways.
- Definitions: DIN — Drug Identification Number; ART — Antiretroviral Therapy; PEP — Post‑Exposure Prophylaxis.
Guidelines For Proper Use (Pharmacist And Provincial Tips)
Pharmacists need clear, standard checklists for safe dispensing and patient counselling.
- Dispense efavirenz only as part of combination ART and confirm the full regimen with the prescriber.
- Screen for psychiatric history, seizure disorders and pregnancy potential; document contraceptive counselling for women of child‑bearing potential.
- Provide bilingual counselling (English/French) where relevant and offer adherence supports such as blister packs or med sync for rural patients.
| Monitoring | Suggested Timing |
|---|---|
| Baseline Liver Function Tests | Before starting and periodically thereafter |
| Psychiatric Symptom Check | At initiation and early follow‑up visits |
| Adherence/Drug Interaction Review | Every refill or sooner if concerns arise |
Storage/Overdose Highlight: Store below 30°C and protect from moisture; overdose causes severe CNS effects — provide supportive care and seek emergency assistance as needed.
Delivery Across Canada (English)
| City | Region | Delivery Time |
|---|---|---|
| Toronto | Ontario | 5‑7 days |
| Montreal | Quebec | 5‑7 days |
| Vancouver | British Columbia | 5‑7 days |
| Calgary | Alberta | 5‑7 days |
| Edmonton | Alberta | 5‑7 days |
| Ottawa | Ontario | 5‑7 days |
| Winnipeg | Manitoba | 5‑7 days |
| Halifax | Nova Scotia | 5‑7 days |
| Victoria | British Columbia | 5‑7 days |
| Saskatoon | Saskatchewan | 5‑9 days |
| Regina | Saskatchewan | 5‑9 days |
| St. John’s | Newfoundland and Labrador | 5‑9 days |
| London | Ontario | 5‑9 days |
